Treatment of patients with stroke has changed substantially during the past 25 years. In 1995, the NINDS rt-PA trial showed among selected patients with acute ischemic stroke who were treated with intravenous alteplase within 3 hours of known stroke onset or last known well time had reduced disability at 3 months.1 In 2008, the ECASS III trial demonstrated benefit of intravenous alteplase among selected patients treated up to 4.5 hours after known stroke onset or last known well time.2 Benefit from alteplase treatment occurred despite higher rates of symptomatic intracranial hemorrhage compared with placebo (6.4% vs 0.6% in the NINDS rt-PA trial; 2.4% vs 0.3% in ECASS III).1,2 More recently, thrombectomy has been shown to substantially reduce morbidity in selected patients with ischemic stroke.3
Powers WJ. Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far? JAMA. 2018;320(2):141–143. doi:10.1001/jama.2018.8511
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: